DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

p53 and Response to Preoperative Radiotherapy for T2 and T3

Information source: Medical University of Vienna
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rectal Cancer

Intervention: preoperative short course radiation (Radiation)

Phase: N/A

Status: Recruiting

Sponsored by: Medical University of Vienna

Official(s) and/or principal investigator(s):
Daniela Kandioler, MD, Study Chair, Affiliation: MUW

Overall contact:
Daniela Kandioler, MD, Phone: +43 1 40400 56210, Email: daniela.kandioler@meduniwien.ac.at


Background: Meta-analyses of large randomized trials proved the superiority of preoperative short course radiation and surgery, as compared with surgery alone. Short course radiation results in a 50% reduction in terms of local relapse in stage II and III rectal cancer patients. Patients with complete pathological remission additionally show a significant survival benefit. Complete pathological remission (pCR) occurs in 8% after preoperative radiation and in >16% if the interval between radiation and surgery is at least 8 weeks. It is generally accepted that mutations in the TP53 gene represent a crucial defect in the apoptosis pathway. Radiation therapy is suggested to act via induction of apoptosis in irradiated cells. Therefore, it is expected that a defect in the TP53 gene has an effect on the success of radiation therapy. Currently available imaging tools are hardly able to diagnose response to radiation therapy correctly, as this does not essentially correlate with tumor size. Method: Aim of this prospective observation study is to strengthen the hypothesis that the TP53 genotype is a promising marker to predict response to radiation therapy in rectal cancer patients. Consequently, the expected results will justify prospective, randomized intervention trials to obtain level of evidence I for the p53 marker hypothesis. Trial endpoint is downstaging and pCR rate. Tumor stage and pathological remission will be evaluated by MRT and pathohistology and correlated to the TP53 genotype of the diagnostic biopsy. Additionally, we will investigate the applicability of novel imaging modalities in magnet resonance tomography to monitor response to radiotherapy. The objective of this study is

- to evaluate the effect of a genetic tumor marker (TP53 genotype) on the response to

preoperative short course radiation (in terms of downstaging and pCR rate)

- to evaluate the applicability of novel magnet resonance tomography imaging modalities

to monitor response to preoperative short time radiation. Conclusion: The prospective evaluation of the potential predictive marker TP53 may bring us one-step closer to an individualized therapy regimen, which allows the restriction of preoperative radiation in rectal cancer to those patients who will benefit.

Clinical Details

Official title: PART1 - a Prospective Phase II Study to Evaluate the Impact of TP53 Gene Mutations in Patients With Preoperative Radiotherapy for T2 and T3 Rectal Cancer

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Interaction between the status of the biomarker TP53 and response to treatment

Secondary outcome:

pCR rate

complete resection rate


overall survival


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: Patients who are eligible for this observational study will be treated according to current standards with preoperative short course radiation (5x5 Gy) and a subsequent interval to surgery of at least 8 to maximum 16 weeks. According to standards of rectal cancer therapy, eligible patients will meet the following criteria:

- Histologically confirmed adenocarcinoma of the rectum

- Tumor staging with MRI

- Inferior margin of the tumor located not farther than 15 cm from anal verge and below

the level of S1-2

- Tumor stage T2 and T3

- No evidence of metastatic disease

- No prior tumor therapy for rectal or pelvic cancers (surgery, radio-, chemo-,

immunotherapy, molecular target therapy, or any other type of tumor therapy)

- Medical fitness of the patient for treatment (decided by the involved physician)

- Patient compliance

- Signed informed consent from the patient or a legal representative, for the analysis

of the tumor including genetic analyses of the tumor DNA. Exclusion Criteria: Patients will be excluded from the study for any of the following reasons

- Clinical stage T1 (appropriate for local excision),

- Clinical stage T4 (Radio/Chemotherapy)

- Clinical stage M+ (distant metastases)

- No tumor staging with MRI

- Inoperability (technical or functional)

- Prior tumor therapy of the pelvis

- Concurrent administration of any other tumor therapy

- Second primary malignancy that is clinically detectable at the time of consideration

for study enrollment

- Serious concomitant disorders or attitudes of the patient that would compromise the

safety of the patient or his/her ability to complete the study.

Locations and Contacts

Daniela Kandioler, MD, Phone: +43 1 40400 56210, Email: daniela.kandioler@meduniwien.ac.at

Medical University of Vienna, Department of Surgery, Vienna 1090, Austria; Recruiting
Additional Information

Homepage of the p53-research group

Related publications:

Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F, Kührer I, Kappel S, Wrba F, Horvath M, Karner J, Renner K, Bergmann M, Karner-Hanusch J, Pötter R, Jakesz R, Teleky B, Herbst F. TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg. 2002 Apr;235(4):493-8.

Starting date: August 2011
Last updated: June 17, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017